Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 5/20 | 0.50 |
| ▸ | METAP2 | P50579 | 3/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28618072 | 0.98 | AXL (0.54) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL767447 | 0.94 | AXL (0.62) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL8404434 | 0.85 | CHEK1 (0.58) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL29769140 | 0.85 | CHEK1 (0.58) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL2579706 | 0.80 | CHEK1 (0.70) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL1273919 | 0.78 | CHEK1 (0.73) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL25038479 | 0.76 | NOS1 (0.50) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL15288335 | 0.76 | AXL (0.51) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL12435218 | 0.76 | CHEK1 (0.48) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL21253484 | 0.76 | FGFR1 (0.60) | AXLNOS1METAP2DYRK1ACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3980412-B1 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12319671-B2 | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| US-12172995-B2 | Substituted indole and indazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024217587-A1 | SUBSTITUTED PYRAZINE COMPOUND HAVING AXL INHIBITORY ACTIVITY | 南京正大天晴制药有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-12030872-B2 | N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2014039831-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-13 | — | — | WO | disclosed |
| EP-2609095-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030872-B2 | N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, CLK2, BRSK2 | AXL 1217/4885NOS1 3114/4885METAP2 3734/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | AXL 4574/4885NOS1 4640/4885METAP2 2978/4885 |
| US-12319671-B2 | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, BRSK2 | AXL 1234/4885NOS1 2922/4885METAP2 3913/4885 |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | GPR119, RPLP2, FOXM1 | AXL 4808/4885NOS1 1339/4885METAP2 4/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | AXL 2401/4885NOS1 1590/4885METAP2 368/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | AXL 4795/4885NOS1 3382/4885METAP2 3437/4885 |
| US-12172995-B2 | Substituted indole and indazole compounds | TLR1, TLR7, IDO1 | AXL 1537/4885NOS1 43/4885METAP2 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.